Want to see RANI full AI Analyst Report?
Top Page
Rani Therapeutics Holdings
(NASDAQ:RANI)
Select Model
Select Model
Rating:48Neutral
Price Target:
$0.79
▼(-6.71% Downside)
Action:Reiterated
Date:08/05/26
The score is held back primarily by weak financial performance—minimal revenue scale, sizable losses, and continued cash burn. Technicals are neutral but still below key longer-term moving averages, while valuation is pressured by negative earnings and no dividend support. Corporate events are mixed, with financing and governance positives offset by Nasdaq bid-price noncompliance risk.
Positive Factors
Proprietary oral biologic delivery platform
Rani’s ingestible RaniPill platform provides a structural competitive advantage by enabling oral delivery of biologics that otherwise require injections. If clinically validated, the platform creates high barriers to entry, broad therapeutic applicability, and long-term licensing and royalty potential.
Negative Factors
Minimal and declining revenue scale
TTM revenue is very small and falling, indicating limited commercialization traction. Low revenue scale makes the business highly milestone‑dependent and lumpy, limits absorption of fixed R&D/G&A costs, and heightens execution risk unless partnerships convert into steady commercial receipts.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary oral biologic delivery platform
Rani’s ingestible RaniPill platform provides a structural competitive advantage by enabling oral delivery of biologics that otherwise require injections. If clinically validated, the platform creates high barriers to entry, broad therapeutic applicability, and long-term licensing and royalty potential.
Read all positive factors
Rani Therapeutics Holdings (RANI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$105.56M
Dividend YieldN/A
Average Volume (3M)910.20K
Price to Earnings (P/E)―
Beta (1Y)2.44
Revenue Growth164.08%
EPS Growth58.49%
CountryUS
Employees71
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding112,389,150
10 Day Avg. Volume1,465,082
30 Day Avg. Volume910,200
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.70
Price to Sales (P/S)54.68
P/FCF Ratio-4.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.50Price Target Upside782.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.19
Revenue Forecast (FY)$4.13M
Rani Therapeutics Holdings Business Overview & Revenue Model
Company Description
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant ...
How the Company Makes Money
Rani Therapeutics is a clinical-stage company and has historically generated revenue primarily from collaboration and license arrangements rather than from sales of approved commercial products. Under these agreements, revenue can come from (1) up...
Rani Therapeutics Holdings Earnings Call Summary
Earnings Call Date:Mar 31, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:Nov 05, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted significant advancements in Rani's technology and pipeline, particularly in the obesity treatment market, supported by strategic partnerships and successful preclinical data. However, financial challenges remain, as evidenced by decreased cash reserves and a substantial net loss for the year.Positive Updates
Advancements in RaniPill Technology
The RaniPill technology, designed for oral delivery of biologics, has shown success in preclinical and clinical trials, achieving high bioavailability for 19 molecules and completing three Phase 1 studies with no serious adverse events.
Negative Updates
Decreased Financial Reserves
Cash, cash equivalents, and marketable securities decreased from $48.5 million in 2023 to $27.6 million in 2024, with funding expected to last into Q3 2025.
Read all updates
Q4-2024 Updates
Positive
Negative
Advancements in RaniPill Technology
The RaniPill technology, designed for oral delivery of biologics, has shown success in preclinical and clinical trials, achieving high bioavailability for 19 molecules and completing three Phase 1 studies with no serious adverse events.
Read all positive updates
Company Guidance
During Rani Therapeutics' fourth quarter and full year 2024 earnings call, guidance was provided on the company's strategic focus and financial outlook. The company emphasized advancements in its RaniPill platform, highlighting its application in obesity and immunology spaces. Rani plans to further develop its RT-114 and semaglutide programs, with RT-114 moving into clinical trials by mid-2025. Financially, Rani reported a net loss of $56.6 million for the full year, an improvement from $67.9 million in 2023, partly due to cost containment measures. The company ended the year with $27.6 million in cash and expects this to fund operations into the third quarter of 2025. Additionally, Rani is exploring partnership opportunities to leverage its platform technology across multiple indications.Rani Therapeutics Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.17M | 1.63M | 1.03M | 0.00 | 0.00 | 2.72M |
| Gross Profit | 3.01M | 733.00K | 1.03M | -822.00K | 0.00 | 2.72M |
| EBITDA | -33.38M | -37.16M | -50.52M | -61.98M | -61.66M | -52.08M |
| Net Income | -29.44M | -29.67M | -30.02M | -33.97M | -30.59M | -8.33M |
Balance Sheet | ||||||
| Total Assets | 51.88M | 58.62M | 36.63M | 57.92M | 108.03M | 124.21M |
| Cash, Cash Equivalents and Short-Term Investments | 43.40M | 49.71M | 27.64M | 48.54M | 98.48M | 117.45M |
| Total Debt | 3.94M | 4.32M | 29.71M | 30.10M | 30.21M | 0.00 |
| Total Liabilities | 16.34M | 17.11M | 33.14M | 32.47M | 34.02M | 2.64M |
| Stockholders Equity | 28.41M | 33.01M | 1.99M | 12.87M | 36.85M | 47.41M |
Cash Flow | ||||||
| Free Cash Flow | -17.11M | -18.80M | -35.76M | -52.47M | -48.13M | -32.75M |
| Operating Cash Flow | -17.06M | -18.71M | -35.50M | -51.24M | -46.52M | -32.24M |
| Investing Cash Flow | -27.71M | -7.03M | 19.81M | 29.86M | -72.44M | -506.00K |
| Financing Cash Flow | 44.00M | 40.30M | 13.59M | 233.00K | 29.00M | 77.15M |
Rani Therapeutics Holdings Technical Analysis
Positive
0.85
Price Trends
0.79
Positive
0.89
Negative
1.21
Negative
Market Momentum
0.01
Negative
54.30
Neutral
39.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RANI, the sentiment is Positive. The current price of 0.85 is above the 20-day moving average (MA) of 0.76, above the 50-day MA of 0.79, and below the 200-day MA of 1.21, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 54.30 is Neutral, neither overbought nor oversold. The STOCH value of 39.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RANI.
Rani Therapeutics Holdings Risk Analysis
Rani Therapeutics Holdings disclosed 98 risk factors in its most recent earnings report. Rani Therapeutics Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Rani Therapeutics Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $192.69M | -4.86 | -52.35% | ― | ― | 27.21% | |
56 Neutral | $81.87M | -2.25 | -241.96% | ― | ― | 55.59% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $105.56M | -1.89 | -245.45% | ― | 164.08% | 58.49% | |
47 Neutral | $363.39M | -9.19 | -56.32% | ― | ― | -59.74% | |
46 Neutral | $74.45M | -1.02 | -318.08% | ― | ― | 20.55% |
* Healthcare Sector Average
RANI
Rani Therapeutics Holdings
0.78
0.23
41.82%
TENX
Tenax Therapeutics
13.05
6.94
113.58%
ANVS
Annovis Bio
1.87
-0.80
-29.96%
PYPD
PolyPid
4.60
1.34
41.10%
ANTX
AN2 Therapeutics, Inc.
5.84
4.76
440.74%
Rani Therapeutics Holdings Corporate Events
Executive/Board Changes
Rani Therapeutics appoints Michelle Gilson to board
Positive
Aug 4, 2026
On August 1, 2026, Rani Therapeutics Holdings appointed Michelle Gilson to its Board of Directors and named her chair of the Audit Committee, strengthening its financial oversight with a director who brings both biotech and capital markets experie...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Rani Therapeutics Appoints New Chief Financial Officer
Positive
Jun 30, 2026
On June 29, 2026, Rani Therapeutics Holdings appointed Nicholas M. Maestas as chief financial officer, principal financial officer and principal accounting officer, succeeding outgoing CFO Svai Sanford. Maestas brings extensive biotech finance and...
Executive/Board ChangesShareholder Meetings
Rani Therapeutics Shareholders Back Board and Auditor at Meeting
Positive
May 29, 2026
Rani Therapeutics Holdings, Inc. held its annual meeting of stockholders on May 28, 2026, with Class A and Class B shareholders voting together as a single class on all items. Stockholders elected all nominated directors to serve until the 2027 an...
Private Placements and Financing
Rani Therapeutics Announces $20 Million Equity Financing
Positive
May 27, 2026
On May 26, 2026, Rani Therapeutics Holdings, Inc. entered into a securities purchase agreement with institutional investors to sell 12,476,637 shares of Class A common stock and pre-funded warrants for 6,214,953 additional shares, at an offering p...
Business Operations and StrategyExecutive/Board ChangesDelistings and Listing ChangesFinancial DisclosuresRegulatory Filings and Compliance
Rani Therapeutics Faces Nasdaq Bid Price Noncompliance Notice
Negative
May 15, 2026
Rani Therapeutics reported first-quarter 2026 results showing contract revenue rising to $1.7 million from $0.2 million a year earlier, a narrowed net loss of $8.0 million versus $12.7 million, and cash, cash equivalents and marketable securities ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.